BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel. Show more
16 Hartum St, Jerusalem, 9777516, Israel
Start AI Chat
Market Cap
487.3M
52 Wk Range
$7.84 - $26.63
Previous Close
$24.12
Open
$24.48
Volume
76,755
Day Range
$23.27 - $24.48
Enterprise Value
218.9M
Cash
71.54M
Avg Qtr Burn
N/A
Insider Ownership
6.17%
Institutional Own.
30.77%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|
